Holen Sie sich die Stockscreener-App
3.88
0.52%
0.02
Handel nachbörslich:
3.88
Y Mabs Therapeutics Inc Aktie (YMAB) Neueste Nachrichten
Y-mAbs neuroblastoma drug endorsed by NCCN (YMAB:NASDAQ) - Seeking Alpha
Naxitamab Therapy Gains NCCN Support for Neuroblastoma By Investing.com - Investing.com India
Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®) - Stock Titan
Cancer Treatment Pioneer Y-mAbs Announces Q1 2025 Earnings Date: Key Updates Coming May 13 - Stock Titan
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025 - The Manila Times
Y-mAbs Therapeutics, Inc. Scheduled to Report Q1 2025 Financial Results on May 13, 2025 - Nasdaq
Short Interest in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Drops By 16.1% - Defense World
Legal & General Group Plc Decreases Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Renaissance Technologies LLC Raises Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline - Yahoo Finance
Insufficient Growth At Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Hampers Share Price - simplywall.st
Y-mAbs Therapeutics (YMAB) Showcases CD38-SADA Data at AACR 2025 - GuruFocus
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
Y-mAbs Therapeutics Presents Preclinical Data on CD38-SADA at 2025 AACR Annual Meeting - Nasdaq
Revolutionary Cancer Treatment: Y-mAbs CD38-SADA Therapy Achieves 20X Faster Clearance Rate in Latest Trial - Stock Titan
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
YMAB Q1 EPS Decreased by Brookline Capital Management - The AM Reporter
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Has $6.44 Million Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Q1 EPS Forecast for Y-mAbs Therapeutics Reduced by Analyst - Defense World
Y-mAbs begins trial for new non-Hodgkin Lymphoma treatment - Investing.com
Y-mAbs begins trial for new non-Hodgkin Lymphoma treatment By Investing.com - Investing.com India
Y-mAbs Therapeutics (YMAB) Begins Phase 1 Trial for Non-Hodgkin - GuruFocus
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma - The Manila Times
Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platform - TipRanks
Y-mAbs Therapeutics Initiates Phase 1 Trial of CD38-SADA Pre-targeted Radioimmunotherapy for Relapsed or Refractory Non-Hodgkin Lymphoma - Nasdaq
Groundbreaking Radioimmunotherapy: Y-mAbs Launches First-in-Human Trial for Advanced Lymphoma Treatment - Stock Titan
When the Price of (YMAB) Talks, People Listen - news.stocktradersdaily.com
Y-mAbs (YMAB) Faces Downgrade as Market Potential Wanes - GuruFocus
Y-mAbs drops as Bank of America downgrades on headwinds to Danyelza - MSN
ITeos Therapeutics Inc (ITOS) Stock: From Low to High in 52 Weeks - investchronicle.com
Y-Mabs Therapeutics Inc Inc. (YMAB) Price Performance: The Role of Supply and Demand - investchronicle.com
Y-Mabs Therapeutics Inc (YMAB) stock: A year of ups and downs - uspostnews.com
Ratio Review: Analyzing Y-Mabs Therapeutics Inc (YMAB)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded by Bank of America to “Underperform” - Defense World
Y-mAbs stock down as Bank of America downgrades (YMAB:NASDAQ) - Seeking Alpha
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Update - Defense World
Vanguard Group Inc. Trims Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Wellington Management Group LLP Sells 3,451 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
ExodusPoint Capital Management LP Buys New Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - The AM Reporter
KLP Kapitalforvaltning AS Acquires New Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Prudential Financial Inc. Lowers Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity (YMAB) - Seeking Alpha
Investing in Oncology: 4 Companies Driving Cancer Treatment Innovation - openPR.com
YMAB LAWSUIT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Fraud Class Action Filed - ACCESS Newswire
Pediatric Neuroblastoma Treatment Market Size in 7MM - openPR.com
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 12% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st
Refractory Metastatic Melanoma Clinical and Non-Clinical - openPR.com
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stake Boosted by Charles Schwab Investment Management Inc. - Defense World
(YMAB) Long Term Investment Analysis - news.stocktradersdaily.com
Top Premarket Decliners - MarketScreener
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
0.88%
2.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):